

10/560862

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airmail No. EV521707552US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 15, 2005

Signature:

(Mary Jane Palma)

15 DEC 2005
Docket No.: ASZB-P09-079
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Leifeng Cheng

Application No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: December 15, 2005

Art Unit: Not Yet Assigned

For: 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-
2-CARBOXAMIDE AND -2-
SULFONAMIDE DERIVATIVES AS CB1
MODULATORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Application No.: Not Yet Assigned

Docket No.: ASZD-P01-079

RECEIVED 15 DEC 2005


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-079.

Dated: December 15, 2005

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for Form 1449A/B/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i>				Complete If Known Application Number Not Yet Assigned Filing Date December 10, 2005 First Named Inventor Leifeng Cheng Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Attorney Docket Number ASZD-P01-079	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Y ^o
		Country Code ¹ -Number ² -Kind Code ³ (if known)	MM-DD-YYYY			
/Z.T.J	BA	EP-0 656 354 A1	06-07-1995	Sanofi	English Abstract Attached	
 /Z.T.J	BB	WO-92/02513 A1	02-20-1992	Fujisawa Pharmaceutical Co., Ltd.		
	BC	WO-01/70700 A1	09-27-2001	Solvay Pharmaceuticals B.V.		
	BE	WO-03/051850 A1	06-26-2003	AstraZeneca AB		
	BD	WO-03/051851 A1	06-26-2003	AstraZeneca AB		

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/Z.	CA J	Akihiro Ohta et al., "Anti-Platelet Aggregation Activity of Some Pyrazines," Biol. Pharm. Bull. 20(10):1076-1081 (1997)		
/Z.T	CB	International Search Report from PCT/SE2004/000970 (10/19/04)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached

Examiner Signature	/Zachary Tucker/	Date Considered	12/27/2007
-----------------------	------------------	--------------------	------------